Yazbek Thierry, Gayet Brice
Department of Digestive Diseases, Montsouris Institute, Paris, France.
JOP. 2012 Jul 10;13(4):433-8. doi: 10.6092/1590-8577/863.
Renal cell carcinoma has shown less response to systemic therapies including chemotherapy, radiotherapy and immunotherapy than other cancers. Metastasis of renal cell carcinoma to the pancreas occurs, even after long term radical nephrectomy, surgical resection remains the only potentially curative intervention. We performed surgery for pancreatic metastatic renal cell carcinoma and analyzed the results.
We retrospectively analyzed 11 patients who had undergone pancreatic resection or metastasectomy at our hospital from January 1994 to January 2010. Patient's demographics, clinical variables, types of pancreatic resections (standard or atypical resection), primary histopathology, surgical outcomes, survival and disease free interval were examined. We compared the standard pancreatic resection to atypical resection (enucleation or enucleo-resection).
Eleven patients underwent 14 pancreatic resections or metastasectomy (3 pancreaticoduodenectomy, 4 distal pancreatectomy, 1 completion of pancreatectomy, 4 enucleations and two enucleo-resections) for pancreatic renal cell carcinoma metastasis. The median age was 73 years, the median time period between nephrectomy and finding of pancreatic metastasis was 11.4 years. One patient showed synchronous pancreatic metastatic lesions on radiology. One patient died from a splenic artery pseudoaneurysm rupture 35 days after the surgery. Major complications occurred in 4 patients with standard resection (one hemoperitoneum, three pancreatic fistulas), and in one patient with atypical resection (duodenal fistula); six patients with standard resection presented postoperative diabetes mellitus. Median survival age was 6.5 years (range 1-9 years). Two patients died of metastatic disease 5 to 6 years, while 7 patients are alive and well 1 to 9 years after surgery.
According to these results and regardless of the small number of cases, atypical resection of metastatic renal cell carcinoma has a high median survival rate even after pancreatic recurrence or distant metastasis. It seems reasonable to favor a good quality of life and less diabetes with a limited atypical resection.
与其他癌症相比,肾细胞癌对包括化疗、放疗和免疫治疗在内的全身治疗反应较差。肾细胞癌可转移至胰腺,即使在长期根治性肾切除术后仍会发生,手术切除仍是唯一可能治愈的干预措施。我们对胰腺转移性肾细胞癌患者进行了手术并分析了结果。
我们回顾性分析了1994年1月至2010年1月在我院接受胰腺切除或转移灶切除术的11例患者。检查了患者的人口统计学、临床变量、胰腺切除类型(标准或非典型切除)、原发组织病理学、手术结果、生存率和无病间期。我们将标准胰腺切除术与非典型切除术(摘除术或摘除-切除术)进行了比较。
11例患者因胰腺肾细胞癌转移接受了14次胰腺切除或转移灶切除术(3例胰十二指肠切除术、4例远端胰腺切除术、1例全胰腺切除术、4例摘除术和2例摘除-切除术)。中位年龄为73岁,肾切除与发现胰腺转移之间的中位时间为11.4年。1例患者影像学检查显示同时存在胰腺转移灶。1例患者术后35天死于脾动脉假性动脉瘤破裂。4例接受标准切除术的患者发生了主要并发症(1例腹腔内出血、3例胰瘘),1例接受非典型切除术的患者发生了主要并发症(十二指肠瘘);6例接受标准切除术的患者术后出现糖尿病。中位生存年龄为6.5岁(范围1-9岁)。2例患者在5至6年后死于转移性疾病,7例患者术后1至9年存活且状况良好。
根据这些结果,尽管病例数量较少,但转移性肾细胞癌的非典型切除术即使在胰腺复发或远处转移后仍具有较高的中位生存率。选择有限的非典型切除术以获得良好的生活质量并减少糖尿病的发生似乎是合理的。